Is HPTX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

202 people get HPTX articles and Market Currents by email alert.

Get email alerts on HPTX »

HEADLINES:

Hyperion Therapeutics Added to NASDAQ Biotechnology Index (NBI)

GlobeNewswire (May 16, 2013)
Hyperion Therapeutics Announces First Quarter 2013 Operating Results

GlobeNewswire (May 9, 2013)
Hyperion Therapeutics to Report First Quarter 2013 Financial Results After Market on May 9, 2013

GlobeNewswire (May 6, 2013)
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA

GlobeNewswire (May 2, 2013)
Hyperion Therapeutics Exercises Option to Acquire Rights to BUPHENYL(R) and AMMONUL(R)

GlobeNewswire (May 2, 2013)
Hyperion Therapeutics to Present at Needham's 12th Annual Healthcare Conference

GlobeNewswire (Apr 25, 2013)
Hyperion Therapeutics Issued Key Patent Pertaining to Use of Fasting Ammonia

GlobeNewswire (Apr 16, 2013)
5 Biotechnology Stocks That Greatly Outperformed The Market In Q1
Brian Nichols • Mon, Apr 15 • 2 Comments
Hyperion Therapeutics Completes Follow-On Offering and Announces Exercise of Underwriters' Over-Allotment Option

GlobeNewswire (Mar 13, 2013)
Hyperion Therapeutics Announces Pricing of Follow-On Offering

GlobeNewswire (Mar 8, 2013)
Hyperion Makes RAVICTI(TM) Available for Shipment to UCD Patients

GlobeNewswire (Feb 28, 2013)
Hyperion Therapeutics Announces Fourth Quarter and Full Year 2012 Operating Results

GlobeNewswire (Feb 25, 2013)
Best-Performing Russell 3000 Stocks Year To Date
Bespoke Investment Group • Mon, Feb 11
Hyperion Therapeutics to Present at the Leerink Swann Global Healthcare Conference

GlobeNewswire (Feb 8, 2013)
Hyperion Therapeutics' RAVICTI(TM) (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders

GlobeNewswire (Feb 1, 2013)
Market Bets On Approval For Hyperion's Ravicti On FDA's 'Hint'
Brian L. Wilson • Thu, Jan 24
Hyperion Notified That FDA Will Not Meet the PDUFA Action Date for Ravicti(TM)

GlobeNewswire (Jan 16, 2013)
Hyperion's Drug Ravicti Likely To Receive FDA Approval
Beacon VP Investments • Wed, Jan 9 • 3 Comments
Upcoming Orphan Drug Approval Decisions For 4 Biopharma Companies
LifeSci Advisors • Thu, Dec 20, 2012 • 2 Comments

To learn more about Seeking Alpha Pro, click here.

Market Bets On Approval For Hyperion's Ravicti On FDA's 'Hint'
Brian L. Wilson • Thu, Jan 24
Hyperion's Drug Ravicti Likely To Receive FDA Approval
Beacon VP Investments • Wed, Jan 9 • 3 Comments
Cowen Maintains An Outperform On Hyperion Therapeutics
Ben Yoffe • Mon, Dec 10, 2012 • 2 Comments
Hyperion Sees Volatility On Pending PDUFA And Rising Short Interest
Brian L. Wilson • Fri, Nov 16, 2012 • 1 Comment
Hyperion Therapeutics: One Stock I'm Adding Post-IPO
Matt Schilling • Fri, Aug 3, 2012 • 2 Comments
Hyperion Therapeutics Goes Public
The Burrill Report • Sun, Jul 29, 2012 • 2 Comments
IPO Preview: Hyperion Therapeutics
IPOdesktop • Wed, Jul 25, 2012 • 1 Comment

Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
5 Biotechnology Stocks That Greatly Outperformed The Market In Q1
Brian Nichols • Mon, Apr 15 • 2 Comments
Best-Performing Russell 3000 Stocks Year To Date
Bespoke Investment Group • Mon, Feb 11
Upcoming Orphan Drug Approval Decisions For 4 Biopharma Companies
LifeSci Advisors • Thu, Dec 20, 2012 • 2 Comments
5 Biotechs With January FDA Decision Date Catalysts
David Zanoni • Mon, Dec 17, 2012
5 Major Insider Buys Filed On August 2
Markus Aarnio • Thu, Aug 2, 2012 • 11 Comments
IPO Preview: Stemline Therapeutics (STML)
IPOdesktop • Tue, Jul 31, 2012 • 2 Comments
8 U.S. IPOs Expected This Week
Renaissance Capital IPO Research • Tue, Jul 24, 2012 • 1 Comment
8 IPOs Scheduled For The Week Of July 23
IPOdesktop • Mon, Jul 23, 2012 • 2 Comments

There are no Transcripts on HPTX.

Hyperion Therapeutics Added to NASDAQ Biotechnology Index (NBI)

GlobeNewswire (May 16, 2013)
Hyperion Therapeutics Announces First Quarter 2013 Operating Results

GlobeNewswire (May 9, 2013)
Hyperion Therapeutics to Report First Quarter 2013 Financial Results After Market on May 9, 2013

GlobeNewswire (May 6, 2013)
Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA

GlobeNewswire (May 2, 2013)
Hyperion Therapeutics Exercises Option to Acquire Rights to BUPHENYL(R) and AMMONUL(R)

GlobeNewswire (May 2, 2013)
Hyperion Therapeutics to Present at Needham's 12th Annual Healthcare Conference

GlobeNewswire (Apr 25, 2013)
Hyperion Therapeutics Issued Key Patent Pertaining to Use of Fasting Ammonia

GlobeNewswire (Apr 16, 2013)
Hyperion Therapeutics Completes Follow-On Offering and Announces Exercise of Underwriters' Over-Allotment Option

GlobeNewswire (Mar 13, 2013)
Hyperion Therapeutics Announces Pricing of Follow-On Offering

GlobeNewswire (Mar 8, 2013)
Hyperion Makes RAVICTI(TM) Available for Shipment to UCD Patients

GlobeNewswire (Feb 28, 2013)
Hyperion Therapeutics Announces Fourth Quarter and Full Year 2012 Operating Results

GlobeNewswire (Feb 25, 2013)
Hyperion Therapeutics to Present at the Leerink Swann Global Healthcare Conference

GlobeNewswire (Feb 8, 2013)
Hyperion Therapeutics' RAVICTI(TM) (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders

GlobeNewswire (Feb 1, 2013)
Hyperion Notified That FDA Will Not Meet the PDUFA Action Date for Ravicti(TM)

GlobeNewswire (Jan 16, 2013)
HALT-HE Study Underscores Role of Ammonia in Hepatic Encephalopathy

GlobeNewswire (Nov 12, 2012)
Hyperion Therapeutics Announces Third Quarter 2012 Operating Results

GlobeNewswire (Nov 7, 2012)
Hyperion Therapeutics to Present at Upcoming Investor Conferences in November

GlobeNewswire (Nov 5, 2012)
Hyperion Therapeutics to Host/Webcast Analyst and Investor Briefing at AASLD

GlobeNewswire (Oct 17, 2012)
Hyperion Therapeutics to Report Results of HALT-HE Study at AASLD Plenary Session

GlobeNewswire (Oct 2, 2012)
Hyperion Therapeutics Announces Second Quarter 2012 Operating Results

GlobeNewswire (Sep 6, 2012)

HPTX vs. ETF Alternatives

Company Description

We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. We are developing Ravicti™ (glycerol phenylbutyrate) to treat the most prevalent urea cycle disorders, or UCD, and hepatic... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 6:19 AM Hyperion Therapeutics (HPTX): Q1 EPS of -$0.52 beats by $0.06. Revenue of $783K beats by $513K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, May 2, 11:45 AM More on Hyperion Therapeutics (HPTX +6.6%): In tandem with the company's announcement of FDA orphan drug exclusivity for Raviciti, the company also says it will exercise its option to acquire Buphenyl Tablets and Powder, an FDA approved therapy for the chronic management of the most prevalent urea cycle disorders, and Ammonul injection 10%/10%, a hospital based product used to treat UCD patients in hyperammonemic crisis, from Valeant Pharmaceuticals (VRX -0.9%). Comment! [Healthcare, On the Move]
Thursday, May 2, 11:39 AM Hyperion Therapeutics (HPTX +6.6%) trades higher today after saying the FDA has granted a seven-year orphan drug exclusivity to its Raviciti Liquid, a treatment for urea cycle disorder. Additionally the company has also received a patent related to the use of Raviciti with optimal measurement timing and target levels for blood ammonia in urea cycle disorder patients, with a term that expires in March, 2032. Comment! [Healthcare, On the Move]
Friday, March 8, 10:36 AM Hyperion Therapeutics (HPTX +3.2%) trades up after the company prices its follow-on offering of 2,875,000 shares of stock at $20.75 per share, just a 0.7% discount to its closing price. Additionally, in response to the high demand, underwriters have been granted a 30-day option to purchase up to an additional 431,250 shares to cover over-allotments. Comment! [Healthcare, On the Move]
Monday, February 4, 1:35 PM Hyperion Therapeutics (HPTX +34%) trades up today after winning FDA approval for its first drug, Ravicti, for treatment of urea cycle disorder - a rare but potentially deadly genetic disorder that affects the urea cycle - in patients aged two and older. The drug removes ammonia from the blood which can't be removed naturally in people with urea cycle disorders. Ammonia in the body can travel to the brain and cause brain damage. The drug is expected to be commercially available in April. Comment! [Healthcare, On the Move]
Monday, February 4, 12:45 PM Midday top 10 gainers: HPTX +31%. APKT +22%. EBOD +16%. PGRX +15%. SONS +14%. PC +11%. EDAP +9%. ORRF +10%. HMY +9%. TAOM +9%.
Midday top 10 Losers: INUV -13%. CLSN -13%. SED -12%. CYTK -8%. VVI -9%. CTC -8%. PRIS -8%. PERI -8%. BLIN -8%. CFBK -8%. Comment! [On the Move]
Wednesday, January 16, 4:29 PM Shares of Hyperion Therapeutics (HPTX +19%) shook off early weakness to close markedly higher today after the FDA advised the company earlier not to expect a final action on its PDUFA date of January 23 for Ravicti, its treatment for Urea Cycle Disorders. The agency told the company that it's continuing to work on label and post-marketing requirements in connection with the New Drug Application. Comment! [Healthcare, On the Move]
Wednesday, January 16, 12:45 PM Midday top 10 gainers: CLRO +49%. NVTL +17%. HPTX +16%. FSGI +16%. CBK +14%. PLBC +13%. BOSC +13%. FSI +12%. CYTR +10%. ADES +10%.
Midday top 10 Losers: GALT -9%. LODE -8%. AMRS -8%. PGNX -8%. IRWD -7%. CROX -7%. GDOT -7%. AXX -7%. YOD -7%. AIM -7%. Comment! [On the Move]
Tuesday, August 28, 2012, 4:10 PM Hyperion Therapeutics (HPTX -1.2%) names Daniel G. Welch to its Board of Directors. Mr. Welch currently serves as Chairman, CEO and President of InterMune (ITMN +1%). Mr. Welch brings more than 30 years of experience in the biotechnology and pharmaceutical industries. 1 Comment [Healthcare]
Thursday, July 26, 2012, 1:08 PM Hyperion Therapeutics (HPTX) opened for trading today at $10.50, up 5% from its initial pricing of 5M shares at $10. The shares have been drifting since, hitting a low of $10.10 before moving slightly higher - last trading at $10.30, +3%. Comment! [Healthcare, On the Move]

HPTX Hyperion Therapeutics

HPTX

Hyperion Therapeutics